ArticleCell reports. Medicine2020
Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Targeting T follicular helper cells for lifelong health.Nature reviews. Drug discovery · 2026Review
- High-resolution promoter interaction analysis implicates genes involved in activation of type 3 innate lymphoid cells in immune disease risk.Nature genetics · 2026Article
- Targeting PD-1Science advances · 2026Article
- High-resolution promoter interaction analysis implicates genes involved in the activation of Type 3 Innate Lymphoid Cells in autoimmune disease risk.bioRxiv : the preprint server for biology · 2026Article
- CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A.Clinical and experimental immunology · 2026Article
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases.Frontiers in immunology · 2026Review
- Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.Human vaccines & immunotherapeutics · 2025Review
- Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.Journal of hematology & oncology · 2025Review
- [Frontier advances in chimeric antigen receptor T cells and chimeric antigen receptor regulatory T cells therapies for autoimmune diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.Cellular & molecular biology letters · 2025Review
- From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology.Clinical and experimental medicine · 2025Article
- Cellular therapies in rheumatic and musculoskeletal diseases.Journal of translational autoimmunity · 2025Review
- Diverse potential of chimeric antigen receptor-engineered cell therapy: Beyond cancer.Clinical and translational medicine · 2025Review
- Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.Signal transduction and targeted therapy · 2024Review
- Current cell therapies for systemic lupus erythematosus.Stem cells translational medicine · 2024Review
- Natural killer cell therapies.Nature · 2024Review
- Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.Nature immunology · 2024Article
- The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment.Frontiers in pharmacology · 2024Review
- From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases.Frontiers in immunology · 2024Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
12 authors at 2 institutions in 1 country.
Seth D ReighardCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Stacey A CranertCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Kelly M RangelCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Ayad AliCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Ivayla E GyurovaCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Arthur T de la Cruz-LynchCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Jasmine A TuazonCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Marat V KhodounDivision of Immunology, Allergy, and Rheumatology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA.
Leah C KottyanCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
David F SmithDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Hermine I BrunnerDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Stephen N WaggonerCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Cincinnati Children's Hospital Medical Center · USVeterans Health Administration · US
Funding
Tissue Repository CoreP30AR070549 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI SHERRY L THORNTON · 2016 to 2026
$7.7MMedical Scientist Training ProgramT32GM063483 · NIGMS · UNIVERSITY OF CINCINNATI · PI KHURANA HERSHEY, GURJIT K. · 2002 to 2022
$6.7MA revolutionary vaccine approach to prevent HIV infection in substance abuseDP1DA038017 · NIDA · CINCINNATI CHILDRENS HOSP MED CTR · PI WAGGONER, STEPHEN N. · 2014 to 2018
$3.9MTargeting natural killer cells to enhance HIV vaccine responsesR01AI148080 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI WAGGONER, STEPHEN N. · 2019 to 2023
$3.3MTranscription Factor Genetics in LupusR01AR073228 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTYAN, LEAH CLAIRE, WAGGONER, STEPHEN N. · 2019 to 2023
$2.2MMechanisms of genetic risk at 2p23 in Eosinophilic EsophagitisR01DK107502 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTYAN, LEAH CLAIRE · 2016 to 2020
$1.8MPathogenesis and therapeutic targeting of immune disordersT32AI118697 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI HILDEMAN, DAVID A · 2016 to 2020
$683kSH800 Cell SorterS10OD023410 · OD · CINCINNATI CHILDRENS HOSP MED CTR · PI THORNTON, SHERRY L · 2017 to 2017
$318kNIAID NIH HHS R01 AI148080NIAID NIH HHS T32 AI118697NIAMS NIH HHS P30 AR070549NIAMS NIH HHS R01 AR073228NIDA NIH HHS DP1 DA038017NIDDK NIH HHS R01 DK107502NIGMS NIH HHS T32 GM063483NIH HHS S10 OD023410
Abstract
Follicular helper T cells (T
Indexed as
AdultAnimalsAutoimmune DiseasesAutoimmunityCells, CulturedChildChild, PreschoolDrosophila melanogasterFemaleHumansImmunotherapy, AdoptiveKiller Cells, NaturalMaleMiceMice, Inbred NODMice, SCIDReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.